Cart
sales@molnova.com
Sebetralstat
CAS No. 1933514-13-6
Sebetralstat( —— )
Catalog No. M35111 CAS No. 1933514-13-6
Sebetralstat (KVD900) is an inhibitor of plasma kallikrein and can be used in studies about metabolic diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 72 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 187 | In Stock |
|
| 50MG | 272 | In Stock |
|
| 100MG | 405 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSebetralstat
-
NoteResearch use only, not for human use.
-
Brief DescriptionSebetralstat (KVD900) is an inhibitor of plasma kallikrein and can be used in studies about metabolic diseases.
-
DescriptionSebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1933514-13-6
-
Formula Weight491.51
-
Molecular FormulaC26H26FN5O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 125 mg/mL (254.32 mM )
-
SMILESCOCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WO2016083820
molnova catalog
related products
-
5-HYDROXYINDOLE-3-AC...
5-Hydroxyindoleacetic acid (5HIAA) is a breakdown product of serotonin that is excreted in the urine. Serotonin and 5HIAA are produced in excess amounts by carcinoid tumors and levels of these substances may be measured in the urine to test for carcinoid tumors (NCI).
-
OVA Peptide 257-264
This is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb.
-
Tilavonemab
Tilavonemab (ABBV-8E12), a humanized anti-tau antibody, targets amino acids 25-30 near the tau protein's N-terminal end. It inhibits the uptake of tau aggregates by human and mouse neurons and diminishes brain atrophy, making it a potential tool in Alzheimer's disease research .
